Involvement of inflammation and its resolution in disease and therapeutics

S Alfaro, V Acuña, R Ceriani, MF Cavieres… - International Journal of …, 2022 - mdpi.com
Inflammation plays a critical role in the response to and survival from injuries and/or
infections. It occurs in two phases: initiation and resolution; however, when these events do …

A New Experimental Model for Assessing Drug Efficacy against Trypanosoma cruzi Infection Based on Highly Sensitive In Vivo Imaging

MD Lewis, AF Francisco, MC Taylor… - Journal of …, 2015 - journals.sagepub.com
The protozoan Trypanosoma cruzi is the causative agent of Chagas disease, one of the
world's major neglected infections. Although development of improved antiparasitic drugs is …

Challenges in Chagas disease drug development

AF Francisco, S Jayawardhana, F Olmo, MD Lewis… - Molecules, 2020 - mdpi.com
The protozoan parasite Trypanosoma cruzi causes Chagas disease, an important public
health problem throughout Latin America. Current therapeutic options are characterised by …

Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage

AF Francisco, S Jayawardhana, MD Lewis, KL White… - Scientific Reports, 2016 - nature.com
The insect-transmitted protozoan parasite Trypanosoma cruzi is the causative agent of
Chagas disease, and infects 5–8 million people in Latin America. Chagas disease is …

Biological factors that impinge on Chagas disease drug development

AF Francisco, S Jayawardhana, MD Lewis, MC Taylor… - Parasitology, 2017 - cambridge.org
Chagas disease is caused by infection with the insect-transmitted protozoan Trypanosoma
cruzi, and is the most important parasitic infection in Latin America. The current drugs …

Pharmacokinetics and tissue distribution of benznidazole after oral administration in mice

L Perin, R Moreira da Silva, KS Fonseca… - Antimicrobial agents …, 2017 - Am Soc Microbiol
Specific chemotherapy using benznidazole (BNZ) for Chagas disease during the chronic
stage is controversial due to its limited efficacy and toxic effects. Although BNZ has been …

Infectious myocarditis: the role of the cardiac vasculature

L Woudstra, LJM Juffermans, AC van Rossum… - Heart Failure …, 2018 - Springer
Infectious myocarditis is the result of an immune response to a microbial infection of the
heart. The blood vessels of the heart, both the intramyocardial microvasculature and the …

Vaccine-linked chemotherapy with a low dose of benznidazole plus a bivalent recombinant protein vaccine prevents the development of cardiac fibrosis caused by …

VM Dzul-Huchim, MJ Ramirez-Sierra… - PLoS Neglected …, 2022 - journals.plos.org
Background Chagas disease (CD) is caused by Trypanosoma cruzi and affects 6–7 million
people worldwide. Approximately 30% of chronic patients develop chronic chagasic …

[HTML][HTML] Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly …

ÁC Cevey, GA Mirkin, FN Penas, NB Goren - International Journal for …, 2016 - Elsevier
Chagas disease, caused by Trypanosoma cruzi, is the main cause of dilated
cardiomyopathy in the Americas. Antiparasitic treatment mostly relies on benznidazole (Bzl) …

Comparing in vivo bioluminescence imaging and the Multi-Cruzi immunoassay platform to develop improved Chagas disease diagnostic procedures and biomarkers …

AF Francisco, U Saade, S Jayawardhana… - PLoS neglected …, 2022 - journals.plos.org
Background Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and is
a serious public health problem throughout Latin America. With 6 million people infected …